Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Submitted by admin on Tue, 04/08/2015 - 7:29pm
Anything relating to the treatment and therapy available for CML
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of higher response rates compared with imatinib.
Armed with all this information, how can you help your body make the most optimal response possible to your TKI therapies?